Fenbendazole is not approved for human use. It is a veterinary deworming drug licensed for animals like dogs, cats, and livestock, and neither the FDA nor the European Medicines Agency has authorized it for any human condition. Despite growing interest online, particularly around claims that it fights cancer, its safety and proper dosing in humans have never been established through clinical trials.
That said, some people are taking it anyway. Here’s what the available evidence actually shows about what happens when they do.
Why People Are Taking It
Fenbendazole gained popularity after social media posts and personal testimonials claimed it could treat cancer. The drug belongs to a family of compounds called benzimidazoles, which kill parasites by disrupting structures inside cells called microtubules. These structures act like scaffolding: cells need them to divide and maintain their shape. Lab research published in Scientific Reports confirmed that fenbendazole does interfere with microtubules in human cancer cells, causing them to stop dividing and eventually die.
That finding sounds promising, but there’s a critical gap. What happens in a petri dish doesn’t reliably predict what happens in a living person. Many substances kill cancer cells in the lab but fail or cause harm in actual patients. No controlled human trial of fenbendazole for cancer has been completed. One research review in the Journal of Korean Medical Science stated plainly that clinical trials with fenbendazole are considered impossible under current regulations because the drug is not permitted for human use due to toxicity concerns.
How the Body Processes Fenbendazole
When a human swallows fenbendazole, the liver breaks it down using specific enzymes, primarily CYP2C19 and CYP2J2. These enzymes convert it into metabolites that the body can eventually eliminate. This matters for two reasons. First, people who have genetic variations affecting these enzymes (which is common, especially for CYP2C19) may process the drug much faster or slower than average, making its effects unpredictable. Second, anyone taking other medications that rely on the same enzymes could experience drug interactions that amplify side effects or reduce the effectiveness of their other treatments.
Because fenbendazole was designed for veterinary use, there is almost no published data on its half-life, absorption rate, or bioavailability in humans. Dosing information circulating online comes from animal formulations, not from human pharmacokinetic studies. This means nobody can say with confidence what a “safe” dose looks like for a person.
Documented Liver Damage
The most serious risk identified so far is liver injury. At least three published case reports describe people who developed significant liver damage after self-administering fenbendazole.
One well-documented case involved a 47-year-old woman with metastatic colon cancer who was also receiving immunotherapy. She started taking 222 mg of fenbendazole three times per week and had no symptoms for six weeks. When she increased to 222 mg daily (a 2.3-fold increase in weekly exposure), she developed severe liver injury within a week. Her liver enzyme levels spiked dramatically, with one marker reaching more than 25 times the normal upper limit. After she stopped taking fenbendazole, her liver function returned to normal within about a month, and she was able to safely resume her cancer immunotherapy.
A separate case report in the ACG Case Reports Journal described another patient who developed severe drug-induced liver injury from self-administering the veterinary product. A third case, published in the American Journal of Gastroenterology, documented a woman with metastatic breast cancer whose liver enzymes climbed rapidly while taking fenbendazole, again resolving after she stopped.
The pattern across all reported cases is consistent: the liver damage appears dose-dependent, develops within days to weeks, and reverses after stopping the drug. That’s the good news. The bad news is that severe liver injury can be life-threatening, particularly in someone whose liver is already under stress from cancer, chemotherapy, or other medications.
How It Differs From Human-Approved Relatives
Fenbendazole has close chemical relatives that are approved for humans. Mebendazole and albendazole are both benzimidazole drugs used to treat parasitic worm infections in people, and they work through the same basic mechanism of disrupting microtubules. These drugs have gone through formal human testing, so their absorption rates, side effect profiles, drug interactions, and safe dosing ranges are well understood.
The fact that closely related drugs are safe for humans does not mean fenbendazole is. Different compounds in the same chemical family can have very different properties once inside the body. Fenbendazole’s specific absorption, metabolism, and tissue distribution in humans remain poorly characterized. Researchers have noted that its pharmacokinetics and safety “have yet to be well-documented in medical literature,” which is exactly the kind of gap that formal clinical trials are designed to fill.
The Social Media Factor
Much of the momentum behind fenbendazole use comes from online communities sharing personal stories. While these accounts feel compelling, they carry serious limitations. People taking fenbendazole for cancer are almost always taking other treatments simultaneously, making it impossible to attribute any improvement to the deworming drug specifically. Negative outcomes, including cases where the drug didn’t help or caused harm, are far less likely to be shared widely.
Medical researchers have flagged this trend directly. A 2024 case report noted that use “appears to be increasing due to the popularization of fenbendazole’s potential anticancer effects by social media” and emphasized that physicians should ask patients about self-administered products that aren’t part of their formal treatment plan. The concern isn’t theoretical: liver damage from fenbendazole can mimic side effects of immunotherapy drugs, potentially leading doctors to stop effective cancer treatment unnecessarily while they sort out the cause.
What the Evidence Adds Up To
Fenbendazole can physically be swallowed by a person, and the body will metabolize it. But “can” and “should” are very different questions. The drug has no approved human indication, no established safe dose for people, no completed human clinical trials, and a small but growing number of case reports showing it can cause serious liver damage. The lab evidence showing anticancer activity is real but preliminary, limited to cell cultures and animal models. For anyone considering it, the core problem is straightforward: you’d be taking an untested drug at a dose nobody has validated, with no way to predict how your body will handle it.